Komori
Pharmarise Holdings (2796) · RiskWorsenedLatest Earnings (2026-09-17): "Mitigated"

Post-M&A integration and goodwill impairment risk

First written in FY2016. 4 of 13 entries say "Restated". Latest entry: 2026-09-17.

13entries
11years
3from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseRestatedFY2016 – FY20222016: 12017: 020172018: 120182019: 020192020: 120202021: 120212022: 120222023: 020232024: 120242025: 220252026: 52026
Same theme, other companies
Post-M&A integration and goodwill impairment riskA theme 474 companies write about · 508 as a headwind · 1 as a tailwind

The whole theme swung hardest in 2024: 36 of 89 companies on the "Worse" side.

25 other companies' latest entry also says "Mitigated".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 187 companies compared. The sentences above are computed from all 187.Comparing 200 of the theme's 509 threads.
Full recordFilings, disclosures and news, newest first
  1. 2026-09-17MitigatedEarnings

    「Goodwill 7,257 7,044」

    The goodwill balance decreased from ¥7,257 million at the end of the previous consolidated fiscal year to ¥7,044 million.
  2. FY2026WorsenedAnnual report

    「Goodwill 6,800 7,257」

    The goodwill balance increased from ¥6,800 million to ¥7,257 million, mainly due to the acquisition of the Sanko Medical Group and other factors. Goodwill attributable to businesses other than the pharmacy business also increased from ¥515 million to ¥1,236 million.
  3. FY2026-H1MitigatedAnnual report

    「Goodwill 6,800 6,477」

    The goodwill balance decreased from ¥6,800 million at the end of the previous fiscal year to ¥6,477 million, reducing balance-based exposure to goodwill impairment risk.
  4. FY2025WorsenedAnnual report

    「Goodwill (pharmacy business) ¥6,284 million Goodwill (businesses other than the pharmacy business) ¥515 million」

    Against the backdrop of M&A and business transfers, the goodwill balance increased from ¥5,917 million in the previous fiscal year to ¥6,800 million. Goodwill attributable to the pharmacy business amounted to ¥6,284 million, and goodwill impairment losses of ¥21 million for the pharmacy business and ¥20 million for businesses other than the pharmacy business were recognized in the current fiscal year.
  5. FY2025-H1MitigatedAnnual report

    「The main factor was that goodwill amounted to ¥5,553 million, down ¥364 million from the end of the previous fiscal year, while」

    The consolidated goodwill balance fell by ¥364 million from the end of the previous fiscal year to ¥5,553 million. Balance-based exposure to goodwill impairment risk has declined.
  6. FY2024WorsenedAnnual report

    「Goodwill (pharmacy business) 1,988 5,273」

    M&A increased the goodwill balance attributable to the pharmacy business from ¥1,988 million to ¥5,273 million, increasing exposure to goodwill impairment risk.
  7. FY2022RestatedAnnual report

    「The group actively pursues M&A to secure economies of scale. When conducting M&A, it performs due diligence on the target company's financial condition and other matters to identify and avoid risks in advance.」

    The company continues to disclose its M&A policy, the risks of post-acquisition problems, failure to meet plans and goodwill impairment, and its due diligence process.
  8. FY2021RestatedAnnual report

    「The group actively pursues M&A to secure economies of scale. When conducting M&A, it performs due diligence on the target company's financial condition and other matters to identify and avoid risks in advance.」

    The company continues to disclose its M&A policy, the risks of post-acquisition problems, failure to meet plans and goodwill impairment, and its due diligence process.
  9. FY2020RestatedAnnual report

    「The group actively pursues M&A to secure economies of scale. When conducting M&A, it performs due diligence on the target company's financial condition and other matters to identify and avoid risks in advance.」

    The company continues to disclose its M&A policy and the risks of post-acquisition problems, failure to meet plans and goodwill impairment.
  10. FY2018RestatedAnnual report

    「When conducting M&A, the company performs due diligence on the target company's financial condition and other matters to identify and avoid risks in advance. However, if unexpected problems arise after an acquisition or business performance fails to progress as planned due to changes in the business environment or other factors, it may become necessary to recognize an impairment loss on goodwill, among other matters.」

    The company continues to disclose its policy of pursuing M&A and the risks of post-acquisition problems, failure to meet plans and goodwill impairment.
  11. FY2016First statedAnnual report

    「If unexpected problems arise after an acquisition or performance fails to progress as planned due to changes in the business environment, it may become necessary to recognize impairment of goodwill.」

    While actively pursuing M&A, the group identifies post-acquisition problems, failure to meet plans and goodwill impairment as risks.
Moved together

"Reliance on Borrowings and Interest-Rate and Financial-Covenant Risks" moved the same way as this thread, in the same document, in 4 of its 13 moves.

433333★123456
  1. ★This thread
  2. 1Reliance on Borrowings and Interest-Rate and Financial-Covenant Risks4×
  3. 2Expanding Scale and Store Network through M&A and New Store Openings3×
  4. 3Family Pharmacies Chosen by Patients and Users3×
  5. 4Strengthening Community Healthcare through Home Healthcare and Institutional Dispensing3×
  6. 5Earnings Volatility From Revisions to Drug Prices and Dispensing Fees3×
  7. 6Downside Risks From the Ukraine Situation, Yen Depreciation and Persistently High Raw Material Prices3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Pharmarise Holdings's next results are scheduled for 2026-09-17. Read the earnings preview It last moved in the Earnings of 2026-09-17: "Mitigated".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.